Loading…
Biodesix, Inc. is projected to rise to $33.38 by 2027, a +56% move from its current price of $21.42. BDSX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $20.33 | $21.44 | $22.60 | +0.09% |
| Jul 14 | $19.91 | $21.46 | $23.13 | +0.17% |
| Jul 15 | $19.59 | $21.47 | $23.54 | +0.26% |
| Jul 16 | $19.33 | $21.49 | $23.90 | +0.34% |
| Jul 17 | $19.11 | $21.51 | $24.22 | +0.43% |
| Jul 18 | $18.91 | $21.53 | $24.51 | +0.51% |
| Jul 19 | $18.73 | $21.55 | $24.79 | +0.60% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $18.73 | $21.55 | $24.79 | +0.60% |
| Week 2 | $17.78 | $21.68 | $26.43 | +1.20% |
| Week 3 | $17.11 | $21.81 | $27.80 | +1.80% |
| Week 4 | $16.57 | $21.94 | $29.03 | +2.41% |
| Week 5 | $16.13 | $22.07 | $30.19 | +3.02% |
| Week 6 | $15.75 | $22.20 | $31.29 | +3.63% |
| Week 7 | $15.41 | $22.33 | $32.36 | +4.25% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Biodesix, Inc. operates as a diagnostic solutions company focused on lung cancer testing. It offers blood-based tests such as Nodify XL2 and Nodify CDT, marketed as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help physicians identify the appropriate treatment pathway and reclassify risk of malignancy in patients with suspicious lung nodules.
It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests as part of the IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient’s immune system to guide treatment decisions. The company delivers diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. It operates laboratories.
Biodesix was formerly known as Elston Technologies, Inc. and changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Biodesix, Inc. (BDSX) trades with a current price of $22.15 and has a market capitalization of $229.38M, ranking 3737 by market cap size. The stock sits in the healthcare sector as a diagnostic solutions provider focused on lung cancer testing and biomarker-driven diagnostics.
The long-term price outlook is bullish, with the 2026 forecast averaging $22.15 and multi-year projections showing meaningful upside into 2050. These forecasts reflect substantial appreciation potential, but they are estimates and not guarantees.
A major floor 54.1% below — a decisive break under it would weaken the trend.
The nearest floor, 30.9% below — buyers have tended to step in here.
The nearest ceiling, 14.4% above — a clean break opens room to run.
A major ceiling 39.8% above — clearing it would confirm fresh momentum.
Key BDSX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BDSX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $21.18 | Buy | $21.45 | Sell |
| MA 10 | $22.21 | Sell | $21.17 | Buy |
| MA 20 | $19.51 | Buy | $19.94 | Buy |
| MA 50 | $16.56 | Buy | $17.49 | Buy |
| MA 100 | $15.50 | Buy | $15.42 | Buy |
| MA 200 | $11.73 | Buy | $13.76 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 58.46 | Neutral |
| Stoch RSI (14) | 11.61 | Buy |
| CCI (20) | 46.27 | Neutral |
| Williams %R (14) | -43.08 | Info |
| MACD (12,26,9) | -0.06 | Sell |
| ROC (12) | 11.80 | Buy |
| Bollinger %B (20,2) | 0.65 | Neutral |
| Stochastic %K (14) | 56.92 | Neutral |
| TRIX (15) | 1.51 | Buy |
| Awesome (5,34) | 3.35 | Buy |
| Ultimate (7,14,28) | 51.44 | Neutral |
| Momentum (10) | 1.38 | Buy |
| Aroon Osc (25) | 52.00 | Buy |
| Hull MA (9) | 20.59 | Buy |
| ADX (14) | 25.23 | Buy |
| ATR (14) | 1.02 | Info |
The 30-day technical picture is bullish in tone. RSI14 is 60, indicating modest positive momentum. The stock trades above the SMA50 of $16.33 and above the SMA200 of $11.66, suggesting since-early-momentum support. Key near-term support is at $14.80 and resistance at $24.50, framing a constructive setup.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $5.46 | $21.42 | $34.15 | 0% | Neutral | |
| $24.25 | $33.38 | $49.67 | +56% | Bullish | |
| $25.08 | $36.66 | $58.11 | +71% | Bullish | |
| $26.60 | $40.94 | $68.09 | +91% | Bullish | |
| $24.04 | $38.76 | $67.11 | +81% | Bullish | |
| $24.12 | $40.64 | $72.82 | +90% | Bullish | |
| $24.60 | $43.20 | $79.80 | +102% | Bullish | |
| $26.86 | $49.11 | $93.22 | +129% | Bullish | |
| $35.89 | $68.21 | $132.75 | +218% | Bullish | |
| $38.09 | $75.22 | $149.78 | +251% | Bullish | |
| $43.06 | $95.69 | $209.30 | +347% | Bullish | |
| $88.30 | $196.22 | $451.30 | +816% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $5.46 | $21.42 | $25.43 | +0.00% |
| August 2026 | $17.88 | $21.65 | $27.32 | +1.09% |
| September 2026 | $18.84 | $23.15 | $29.81 | +6.90% |
| October 2026 | $18.34 | $22.80 | $29.86 | -1.51% |
| November 2026 | $18.27 | $22.95 | $30.50 | +0.68% |
| December 2026 | $20.00 | $25.36 | $34.15 | +10.52% |
Click any year to see its month-by-month BDSX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, BDSX is projected to trade between $5.46 and $34.15, averaging $21.42 — a potential gain of 0% from today's $21.42. Price action looks broadly range-bound.
Biodesix, Inc.'s 2027 outlook centres on $33.38, within a $24.25 to $49.67 range. That is up +56% on the projected 2026 average. That marks a +56% change versus current levels. Buyers look set to stay in control over this stretch.
By 2028, BDSX could reach as high as $58.11, with a base case around $36.66 and support toward $25.08 — roughly +71% from $21.42. Momentum favours further upside here.
Expect BDSX to range from $26.60 to $68.09 through 2029. The $40.94 average target implies a +91% move from current prices. That is up +12% on the projected 2028 average. Buyers look set to stay in control over this stretch.
The BDSX price prediction for 2030 points to an average of $38.76 (low $24.04, high $67.11) — a potential gain of +81% on today's $21.42. Momentum favours further upside here.
In 2031, BDSX is projected to trade between $24.12 and $72.82, averaging $40.64 — a potential gain of +90% from today's $21.42. That is up +5% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Biodesix, Inc.'s 2032 outlook centres on $43.20, within a $24.60 to $79.80 range. That is up +6% on the projected 2031 average. That marks a +102% change versus current levels. Momentum favours further upside here.
By 2033, BDSX could reach as high as $93.22, with a base case around $49.11 and support toward $26.86 — roughly +129% from $21.42. Buyers look set to stay in control over this stretch.
Expect BDSX to range from $35.89 to $132.75 through 2034. The $68.21 average target implies a +218% move from current prices. That is up +39% on the projected 2033 average. Momentum favours further upside here.
The BDSX price prediction for 2035 points to an average of $75.22 (low $38.09, high $149.78) — a potential gain of +251% on today's $21.42. Buyers look set to stay in control over this stretch.
In 2040, BDSX is projected to trade between $43.06 and $209.30, averaging $95.69 — a potential gain of +347% from today's $21.42. That is up +27% on the projected 2035 average. Momentum favours further upside here.
Biodesix, Inc.'s 2050 outlook centres on $196.22, within a $88.30 to $451.30 range. That is up +105% on the projected 2040 average. That marks a +816% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in BDSX today (≈ 46.685341 BDSX) could be worth
$9,160.57
+$8,160.57 (+816%) by 2050 · US Dollar
Based on the average projected BDSX price of $196.22 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BDSXwould be worth at today's price.
$1,000 invested in BDSX on Jul 10, 2025 (≈ 163.934429 BDSX) would be worth
$3,511.48
+$2,511.48 (+251.1%) today · 3.51× · US Dollar
Based on a BDSX entry price of $6.1 vs. today's $21.42.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $21.99 | $974.08 | -2.6% |
| 1 month ago | $15.01 | $1,427.05 | +42.7% |
| 3 months ago | $13.13 | $1,631.38 | +63.1% |
| 6 months ago | $8.08 | $2,650.99 | +165.1% |
| 1 year ago | $6.1 | $3,511.48 | +251.1% |
| All time (5.0y) ago | $241.8 | $88.59 | -91.1% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BDSX forecast.
Our base-case forecast reaches $43.00 around 2032.
Implied market cap at $43.00: $445.3M
The multi-year forecast shows rising option values with a bullish sentiment across the horizon. For 2027 the average price is $35.24 with a 59.1% ROI and bullish sentiment; 2028 shows an average of $38.63 with a 74.4% ROI; 2029 a $43.41 average with a 96% ROI; 2030 an average of $41.04 with an 85.3% ROI. The forecast continues to rise in later years, reaching a 2031 average of $43.28 (95.4% ROI), 2032 $46.62 (110.5% ROI), 2033 $53.67 (142.3% ROI), 2034 $74.78 (237.6% ROI), and 2035 $82.28 (271.5% ROI).
By 2040 the average is $107.13 with a 383.7% ROI, and by 2050 the average is $219.11 with an 889.2% ROI, all with bullish sentiment. These are projected estimates and not guarantees, reflecting potential upside and associated uncertainties inherent in long-range forecasts.
Tap a question to reveal the answer.
The forecast lists year 2030 with min $25.37, avg $41.04, max $71.24 and a ROI of 85.3%, with bullish sentiment.
Forecasts show bullish sentiment from 2027 onward, with ROIs of 59.1% in 2027, 74.4% in 2028, 96% in 2029, 85.3% in 2030, 95.4% in 2031, 110.5% in 2032, 142.3% in 2033, 237.6% in 2034, 271.5% in 2035, 383.7% in 2040, and 889.2% in 2050. The 2026 forecast is neutral with a 0% ROI.
Yes. In 2033 the max forecast is $102.20, which exceeds $100; by 2040 the average is $107.13, indicating upside beyond $100 in the longer term.
Current price is $22.15 and market cap is $229.38M, with a rank of 3737.
Sentiment is BULLISH. RSI14 is 60; the SMA50 is $16.33 and the SMA200 is $11.66. Support stands at $14.80 and resistance at $24.50. The 30-day price range is $15.49 to $31.66, and annualized volatility is 100%.
Biodesix, Inc. Community Discussion
0Share your Biodesix, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.